Inhalation Aerosols (3rd Ed.) Physical and Biological Basis for Therapy, Third Edition Lung Biology in Health and Disease Series
Coordonnateurs : Hickey Anthony J., Mansour Heidi M.
Inhalation aerosols continue to be the basis for successful lung therapy for several diseases, with therapeutic strategies and the range of technology significantly evolving in recent years.
In response, this third edition takes a new approach to reflect the close integration of technology with its application. After briefly presenting the general considerations that apply to aerosol inhalation, the central section of the book uses the focus on disease and therapeutic agents to illustrate the application of specific technologies.
The final integrated strategies section draws the major points from the applications for disease targets and drug products.
PART I Fundamentals. 1. Physicochemical Properties of Respiratory Particles and Formulations. 2. Particle Deposition in the Respiratory Tract and the Effect of Respiratory Disease. 3. Mathematical Modeling of Inhaled Therapeutic Aerosol Deposition in the Respiratory Tract. 4. Lung Transporters and Absorption Mechanisms in the Lungs. 5. Bioavailability of Inhaled Compounds. 6. 3D Models as Tools for Inhaled Drug Development. 7. Overview of the Delivery Technologies for Inhalation Aerosols. PART II Applications, Influence of Lung Disease Pathophysiology on Aerosol Deposition, Inhaler Device Technique in Respiratory Disease, and Clinical Outcomes in Drug Performance Assessment. 8. Neonatal and Pediatric Inhalation Drug Delivery. 9. Asthma. 10. Drug Delivery in Pulmonary Aspergillosis. 11. Lung Cancer Inhalation Therapeutics. 12. Inhaled Therapeutics in Chronic Obstructive Pulmonary Disease. 13. Cystic Fibrosis Infection and Biofilm Busters. 14. Current and Future CFTR Therapeutics. 15. Innate and Adaptive Barrier Properties of Airway Mucus. 16. Nontuberculous Mycobacteria. 17. Inhalational Therapies for Non-Cystic Bronchiectasis. 18. Pulmonary Fibrosis. 19. Therapeutics in Pulmonary Hypertension. 20. Overview of Lung Surfactant and Respiratory Distress Syndrome. 21. Surfactant Aerosol Therapy for nRDS and ARDS. 22. Fundamentals in Nasal Drug Delivery. 23. Inhaled therapeutics against TB: The Promise of Pulmonary Treatment and Prevention Strategies in the Clinic. PART III Integrated Strategies (Reflecting Combined Elements from Chapters 8 through 23). 24. Inhaled Medication: Factors That Affect Lung Deposition. 25. A Critical Perspective on Future Developments Based on the Knowledge We Have Now. 26. Ensuring Effectiveness and Reproducibility of Inhaled Drug Treatment. 27. Conclusion.
Date de parution : 12-2020
21x28 cm
Date de parution : 03-2019
21x28 cm
Thèmes d’Inhalation Aerosols :
Mots-clés :
Tobramycin Inhalation Solutions; Inhaled Tobramycin Powder; CFTR Modulator; NTM Lung Disease; F508del CFTR Mutation; NRF2 Activator; DPIs; DPI Technology; Non-invasive Ventilation; Inhaled Corticosteroids; Aerosol Bolus; Mouth Throat Deposition; COPD Patient; Vibrating Mesh Nebulizers; Aerodynamic Particle Size Distribution; CFTR; Jet Nebulizers; Μm MMAD; Idiopathic Pulmonary Fibrosis; Particle Deposition; CFTR Protein; non-CF Bronchiectasis; NTM Infection; IPF Treatment; MPPD Model